Drug Trial Radar · NCT01235741
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Last checked: Nov 20, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
213
Actual
Start
Jan 2011
Primary completion
Sep 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Takeda Pharmaceuticals North America, Inc.
- First posted
- Nov 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1 of 2 treatment arms (pramlintide+metreleptin or placebo) to begin a 16-week treatment period during which the effect on body weight of treatment with pramlintide+metreleptin will be compared to placebo. Following the 16 week blinded core treatment period, subjects will discontinue study medication for a period of 12 weeks. Following the 12 week off-drug follow-up period, subjects in both groups will initiate a 12 week open-label treatment period with Pramlintide+Metreleptin. During the 12 week off-drug and 12 week open label treatment periods, subjects will continue to participate in a Lifestyle Intervention (LSI) program.
Conditions
- Obesity
Interventions
Pramlintide+MetreleptinDrug
Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
PlaceboDrug
Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat PopulationTime frame: Day 1 up to Month 6 Follow-Up
- Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat PopulationTime frame: Baseline to Month 6 Follow Up
- Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat PopulationTime frame: Week 1 to Month 6 Follow-Up
- Number of Participants With Neutralizing Activity to Metreleptin at Early Termination or During Post Treatment Follow-Up - Intent to Treat Population Who Received MetreleptinTime frame: Baseline to Month 6 Follow-Up
- Number of Participants With Hematology and Urinalysis Laboratory Values of Potential Clinical Importance - Intent to Treat PopulationTime frame: Screening to 6 Month Follow-Up
- Number of Participants With Chemistry Laboratory Value of Potential Clinical Importance - Intent to Treat PopulationTime frame: Screening to Month 6 Follow-Up
- Mean Change From Baseline to Month 6 Follow-Up in Blood Pressure - Intent to Treat PopulationTime frame: Baseline to Month 6 Follow-Up
- Mean Change From Baseline to Month 6 Follow-Up in Heart Rate - Intent to Treat PopulationTime frame: Baseline up to Month 6 Follow-Up
- Mean Change From Baseline to 6 Month Follow-Up in Fasting Plasma Glucose - Intent to Treat PopulationTime frame: Baseline to 6 Month Follow-Up
- Mean Change From Baseline to Month 6 Follow-Up in Insulin - Intent to Treat PopulationTime frame: Baseline up to Month 6 Follow-Up
- Mean Change From Baseline to Month 6 Follow-Up in Lipids - Intent to Treat PopulationTime frame: Baseline up to Month 6 Follow-Up
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Greenbrae, California
Research Site
La Jolla, California
Research Site
Denver, Colorado
Research Site
Winter Park, Florida
Research Site
Chicago, Illinois
Research Site
Baton Rouge, Louisiana
Research Site
Hyattsville, Maryland
Research Site
Boston, Massachusetts
Research Site
St Louis, Missouri
Research Site
Butte, Montana
Research Site
New York, New York
Research Site
Tulsa, Oklahoma
Research Site
Philadelphia, Pennsylvania
Research Site
Austin, Texas
Research Site
Salt Lake City, Utah
Research Site
Arlington, Virginia
Research Site
Norfolk, Virginia
Research Site
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.